PBIRG Annual General Meeting 2014
PBIRG AGM 2014: Disruptive Change
This year’s PBIRG conference took place in Atlanta Georgia, May 18-21. Representing Research Partnership were US President, Harriet Kozak and Director, Claire Richardson.
Is MINT the next BRIC?
In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all poised for massive economic growth. Earlier this year, O’Neill came out of retirement to generate buzz about ‘MINT’ – that’s Mexico, Indonesia, Nigeria and Turkey to the uninitiated – as the next generation ‘ones to watch’ in the coming twenty years.
So what does this mean to the healthcare market and to us as market researchers? With almost 40% of studies conducted by Research Partnership last year having included at least one emerging market, we are well aware that growing economies often translate to growing spend on healthcare and pharmaceuticals – and therefore increasing interest from our clients.
The Next Billion Patients
Published in eyeforpharma 15 April 2014 by Marc Yates
Whilst BRIC is still a key focus, there are signs that pharma is beginning to look at capturing previously untapped segments in these markets and beyond.
Up until now multinational pharmaceutical companies have focused their efforts almost exclusively on the richest patients living in the biggest cities. Taking China as an example, 63% of the revenue of those treatments not included on the Essential Drug List has come from the largest hospitals (Tier 3), half of which comes from just three cities (Beijing, Shanghai and Guangzhou).
However, as competition in the emerging markets is becoming increasingly fierce, so the industry is looking for new growth opportunities. The question is - what are the growth opportunities and what do pharmaceutical companies have to do to leverage these?
The power of observation in gathering patient insights
Published in eyeforpharma 10 April 2014 by Mary Assimakopoulos
If you think of market research you probably think of the traditional interview, where the respondent is asked to answer a number of questions on a particular topic. However, we can also conduct research where the interviewer or moderator takes a much less active role, becoming more of an observer than a participant.
Biosimilars: Friend or Foe?
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.